Imfinzi® (durvalumab) – New indication
February 16, 2018 - The FDA announced the approval of AstraZeneca’s Imfinzi (durvalumab), for the treatment of patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Top